SOUTH SAN FRANCISCO, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced it will host a conference call and webcast on Tuesday, September 26, 2023 at 8:00 a.m. ET | 5:00 a.m. PT to discuss the interim results from the INTEGRIS-PSC Phase 2a trial. Members of Pliant’s management will be joined by Gideon Hirschfield, FRCP, Ph.D., Lily and Terry Horner Chair in Autoimmune Liver Disease at the University of Toronto and a principal investigator in the INTEGRIS-PSC trial.

2023年9月25日（GLOBE NEWSWIRE）-Pliant Therapeutics，Inc。（纳斯达克股票代码：PLRX）今天宣布将于2023年9月26日星期二上午8:00召开电话会议和网络广播。上午5:00讨论INTEGRIS-PSC 2a期试验的中期结果。Pliant管理层的成员将加入多伦多大学自身免疫性肝病Gideon Hirschfield，FRCP博士，Lily和Terry Horner主席以及INTEGRIS-PSC试验的首席研究员。

The conference call will be simultaneously webcast online and will be accessible from the Events & Presentation section of Pliant’s website. The live audio of the conference call can be accessed by telephone by registering in advance at the following link: Pliant Therapeutics INTEGRIS-PSC Conference Call.

电话会议将同时在线进行网络广播，并可从Pliant网站的活动和演示部分访问。可以通过以下链接预先注册通过电话访问电话的实时音频：Pliant Therapeutics INTEGRIS-PSC电话会议。

Upon registration, all telephone participants will receive the dial-in number along and a unique passcode to access the call. An archived replay of the webcast will be available on Pliant’s website for 60 days following completion of the event. About Pliant Therapeutics, Inc. Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis.

注册后，所有电话参与者将收到拨号号码和唯一的密码以访问电话。事件完成后，Pliant网站上将提供网络广播的存档重放60天。关于Pliant Therapeutics，Inc。Pliant Therapeutics是一家临床阶段的生物制药公司，专注于发现和开发治疗纤维化的新疗法。

Pliant's lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. Bexotegrast has received Fast Track Designation and Orphan Drug Designation from the U.S.

Pliant的主要候选产品bexotegrast（PLN-74809）是一种口服，小分子，双选择性αvβ6和αvβ1整合素抑制剂，正在开发用于治疗特发性肺纤维化或IPF的主要适应症，以及原发性硬化性胆管炎或PSC。Bexotegrast已获得美国的快速通道指定和孤儿药指定。

Food and Drug Administration (FDA) in IPF and PSC and Orphan Drug Designation from the European Medicines Agency in IPF and PSC. Pliant has initiated BEACON-IPF, a Ph.

IPF和PSC中的食品和药物管理局（FDA）以及欧洲药品管理局在IPF和PSC中指定的孤儿药。Pliant已启动BEACON-IPF，Ph。